Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy
2016 Ricciuti, B; Mencaroni, C; Paglialunga, L; Paciullo, F; Crino, L; Chiari, R; Metro, G
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
2012 Fabi, A; Russillo, M; Ferretti, G; Metro, G; Nistico, C; Papaldo, P; De Vita, F; D'Auria, G; Vidiri, A; Giannarelli, D; Cognetti, F
Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile?
2011 Russillo, M; Di Benedetto, A; Metro, G; Ferretti, G; Papaldo, P; Cognetti, F; Mottolese, M; Fabi, A
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme
2010 Metro, G; Fabi, A; Mirri, Ma; Vidiri, A; Pace, A; Carosi, M; Russillo, M; Maschio, M; Giannarelli, D; Pellegrini, D; Pompili, A; Cognetti, F; Carapella, Cm
Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity
2017 Inno, A; Metro, G; Bironzo, P; Grimaldi, Am; Grego, E; Di Nunno, V; Picasso, V; Massari, F; Gori, S
Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies
2010 Fabi, A; Metro, G; Di Benedetto, A; Nistico, C; Vici, P; Melucci, E; Antoniani, B; Perracchio, L; Sperduti, I; Milella, M; Cognetti, F; Mottolese, M
The safety of nivolumab for the treatment of advanced non-small cell lung cancer
2017 Metro, G; Ricciuti, B; Brambilla, M; Baglivo, S; Soli, I; Minenza, E; Leonardi, Gc; D'Arpino, A; Colabrese, D; Tazza, M; Zicari, D; Minotti, V; Chiari, R
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study
2010 Fabi, A; Metro, G; Vidiri, A; Lanzetta, G; Carosi, M; Telera, S; Maschio, M; Russillo, M; Sperduti, I; Carapella, Cm; Cognetti, F; Pace, A
Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer"
2016 Metro, G; Chiari, R
Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
2014 Vaccaro, V; Fabi, A; Vidiri, A; Giannarelli, D; Metro, G; Telera, S; Vari, S; Piludu, F; Carosi, Ma; Villani, V; Cognetti, F; Pompili, A; Marucci, L; Carapella, Cm; Pace, A
In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy
2010 Metro, G; Zheng, Z; Fabi, A; Schell, M; Antoniani, B; Mottolese, M; Monteiro, An; Vici, P; Rivera, Sl; Boulware, D; Cognetti, F; Bepler, G
Novel molecular trends in the management of advanced non-small-cell lung cancer
2012 Metro, G; Crinò, L
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
2011 Fabi, A; Di Benedetto, A; Metro, G; Perracchio, L; Nistico, C; Di Filippo, F; Ercolani, C; Ferretti, G; Melucci, E; Buglioni, S; Sperduti, I; Papaldo, P; Cognetti, F; Mottolese, M
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'
2015 Foglietta, J; Metro, G; Crino, L; Gori, S
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis
2015 Genestreti, G; Tiseo, M; Kenmotsu, H; Kazushige, W; Di Battista, M; Cavallo, G; Carloni, F; Bongiovanni, A; Burgio, Ma; Casanova, C; Metro, G; Scarpi, E; Korkmaz, T; Selcuk, S; Roopa, K; Califano, R
Advances on EGFR mutation for lung cancer
2012 Metro, G; Crinò, L
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center
2011 Fabi, A; Felici, A; Metro, G; Mirri, A; Bria, E; Telera, S; Moscetti, L; Russillo, M; Lanzetta, G; Mansueto, G; Pace, A; Maschio, M; Vidiri, A; Sperduti, I; Cognetti, F; Carapella, Cm
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer
2012 Gori, S; Montemurro, F; Spazzapan, S; Metro, G; Foglietta, J; Bisagni, G; Ferzi, A; Silva, Rr; Gamucci, T; Clavarezza, M; Stocchi, L; Fabi, A; Cognetti, F; Torrisi, E; Crivellari, D
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015 Califano, R; Abidin, A; Tariq, Nu; Economopoulou, P; Metro, G; Mountzios, G
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines
2011 Vici, P; Fabi, A; Metro, G; Sergi, D; Giannarelli, D; Di Lauro, L; Bepler, G; Tomao, F; Cognetti, F; Conti, F; Lopez, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy | 2016 | Ricciuti, B; Mencaroni, C; Paglialunga, L; Paciullo, F; Crino, L; Chiari, R; Metro, G | |
| Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy | 2012 | Fabi, A; Russillo, M; Ferretti, G; Metro, G; Nistico, C; Papaldo, P; De Vita, F; D'Auria, G; Vidiri, A; Giannarelli, D; Cognetti, F | |
| Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile? | 2011 | Russillo, M; Di Benedetto, A; Metro, G; Ferretti, G; Papaldo, P; Cognetti, F; Mottolese, M; Fabi, A | |
| Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme | 2010 | Metro, G; Fabi, A; Mirri, Ma; Vidiri, A; Pace, A; Carosi, M; Russillo, M; Maschio, M; Giannarelli, D; Pellegrini, D; Pompili, A; Cognetti, F; Carapella, Cm | |
| Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity | 2017 | Inno, A; Metro, G; Bironzo, P; Grimaldi, Am; Grego, E; Di Nunno, V; Picasso, V; Massari, F; Gori, S | |
| Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies | 2010 | Fabi, A; Metro, G; Di Benedetto, A; Nistico, C; Vici, P; Melucci, E; Antoniani, B; Perracchio, L; Sperduti, I; Milella, M; Cognetti, F; Mottolese, M | |
| The safety of nivolumab for the treatment of advanced non-small cell lung cancer | 2017 | Metro, G; Ricciuti, B; Brambilla, M; Baglivo, S; Soli, I; Minenza, E; Leonardi, Gc; D'Arpino, A; Colabrese, D; Tazza, M; Zicari, D; Minotti, V; Chiari, R | |
| Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study | 2010 | Fabi, A; Metro, G; Vidiri, A; Lanzetta, G; Carosi, M; Telera, S; Maschio, M; Russillo, M; Sperduti, I; Carapella, Cm; Cognetti, F; Pace, A | |
| Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer" | 2016 | Metro, G; Chiari, R | |
| Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas | 2014 | Vaccaro, V; Fabi, A; Vidiri, A; Giannarelli, D; Metro, G; Telera, S; Vari, S; Piludu, F; Carosi, Ma; Villani, V; Cognetti, F; Pompili, A; Marucci, L; Carapella, Cm; Pace, A | |
| In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy | 2010 | Metro, G; Zheng, Z; Fabi, A; Schell, M; Antoniani, B; Mottolese, M; Monteiro, An; Vici, P; Rivera, Sl; Boulware, D; Cognetti, F; Bepler, G | |
| Novel molecular trends in the management of advanced non-small-cell lung cancer | 2012 | Metro, G; Crinò, L | |
| HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care | 2011 | Fabi, A; Di Benedetto, A; Metro, G; Perracchio, L; Nistico, C; Di Filippo, F; Ercolani, C; Ferretti, G; Melucci, E; Buglioni, S; Sperduti, I; Papaldo, P; Cognetti, F; Mottolese, M | |
| Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA' | 2015 | Foglietta, J; Metro, G; Crino, L; Gori, S | |
| Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis | 2015 | Genestreti, G; Tiseo, M; Kenmotsu, H; Kazushige, W; Di Battista, M; Cavallo, G; Carloni, F; Bongiovanni, A; Burgio, Ma; Casanova, C; Metro, G; Scarpi, E; Korkmaz, T; Selcuk, S; Roopa, K; Califano, R | |
| Advances on EGFR mutation for lung cancer | 2012 | Metro, G; Crinò, L | |
| Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center | 2011 | Fabi, A; Felici, A; Metro, G; Mirri, A; Bria, E; Telera, S; Moscetti, L; Russillo, M; Lanzetta, G; Mansueto, G; Pace, A; Maschio, M; Vidiri, A; Sperduti, I; Cognetti, F; Carapella, Cm | |
| Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer | 2012 | Gori, S; Montemurro, F; Spazzapan, S; Metro, G; Foglietta, J; Bisagni, G; Ferzi, A; Silva, Rr; Gamucci, T; Clavarezza, M; Stocchi, L; Fabi, A; Cognetti, F; Torrisi, E; Crivellari, D | |
| Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer | 2015 | Califano, R; Abidin, A; Tariq, Nu; Economopoulou, P; Metro, G; Mountzios, G | |
| Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines | 2011 | Vici, P; Fabi, A; Metro, G; Sergi, D; Giannarelli, D; Di Lauro, L; Bepler, G; Tomao, F; Cognetti, F; Conti, F; Lopez, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista69176
- 4 Contributo in Atti di Convegno ...1
Data di pubblicazione
- In corso di stampa72
- 2020 - 202615564
- 2010 - 201926165
- 2000 - 200915952
- 1990 - 19997577
- 1980 - 19893194
- 1970 - 1979647
- 1968 - 19696
Editore
- Elsevier BV:PO Box 211, 1000 AE A...209
- Elsevier Science Limited:Oxford F...102
- American Institute of Physics:2 H...68
- Il Sole 24 Ore Edagricole:via Goi...67
- Springer Verlag Germany:Tiergarte...54
- American Chemical Society:1155 Si...52
- Annali Della Facolta di Agraria:U...44
- Royal Society of Chemistry:Thomas...41
- John Wiley & Sons Incorporated:Cu...40
- Giuffre Editore Spa:via Busto Ars...37
Rivista
- PHYSICS LETTERS. SECTION B828
- PHYSICAL REVIEW D, PARTICLES, FIE...675
- PHYSICAL REVIEW LETTERS651
- JOURNAL OF HIGH ENERGY PHYSICS530
- PHYSICAL REVIEW D361
- THE JOURNAL OF CHEMICAL PHYSICS290
- PLOS ONE286
- BLOOD273
- THE EUROPEAN PHYSICAL JOURNAL. C,...268
- NUCLEAR INSTRUMENTS & METHODS IN ...261
Serie
- STUDI E INTERVENTI1
Keyword
- Humans2084
- Female1055
- Male976
- Aged629
- Italy623
- Middle Aged602
- Adult532
- Animals396
- COVID-19374
- 80 and over269
Lingua
- eng51182
- ita13305
- fre260
- spa214
- lat88
- por85
- ger64
- und60
- enm53
- rus26
Accesso al fulltext
- no fulltext67643
- open1509
- reserved23
- partially open1
- restricted1